Author | Conference | Journal | Organization | Year | DOI
Look for results that meet for the following criteria:
Academic
Publications
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer

Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic c

Edit
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer   (Citations: 1)
BibTex | RIS | RefWorks Download
Journal: Acta Oncologica - ACTA ONCOL , vol. 49, no. 3, pp. 395-396, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...In addition, Dohn et al. [6] reported on a cohort of 62 colorectal cancer patients receiving bevacizumab infusions over 10 min without any treatment-related HSR...
    • ...The present retrospective study in NSCLC patients confirms the results of Dohn et al. and Mahfoud et al. [6, 7] in colorectal cancer patients regarding the feasibility of bevacizumab 7.5 mg/kg over 10 min...

    Olivier Mir, et al. Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC pati...

Sort by:

Citations (1)

Share this on